BRCA1 sirna

BRCA1 siRNA (Mouse)

Cat. Num. AAA8216073

• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: BRCA1; BRCA1 siRNA (Mouse); Breast cancer type 1 susceptibility protein homolog; BRCA1 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: BRCA1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1,812

• Applicable Applications for BRCA1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse BRCA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for BRCA1 sirna

siRNA to inhibit BRCA1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 161016835
• NCBI GeneID: 12189
• NCBI Accession #: NP_033894.3
• NCBI GenBank Nucleotide #: NM_009764.3
• UniProt Accession #: P48754; Q60957; Q60983; A2A4Q4
• Molecular Weight: 198,795 Da
• NCBI Official Full Name: breast cancer type 1 susceptibility protein homolog
• NCBI Official Synonym Full Names: breast cancer 1
• NCBI Official Symbol: Brca1
• NCBI Protein Information: breast cancer type 1 susceptibility protein homolog
• UniProt Protein Name: Breast cancer type 1 susceptibility protein homolog
• Protein Family: BRCA1-A complex
• UniProt Gene Name: Brca1
• UniProt Entry Name: BRCA1_MOUSE

Uniprot Description

BRCA1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACC1 and preventing its dephosphorylation. Defects in BRCA1 are a cause of genetic susceptibility to breast cancer. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association may be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts (via BRCT domains) with CTIP. Associates with RNA polymerase II holoenzyme. Interacts with SMC1 and COBRA1. Interacts (via BRCT domains) with BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with Artemis and claspin. Interacts with H2AFX (phosphorylated on S140). Interacts with CHK1. Interacts with BRCC3. Five human isoforms are produced by alternative splicing and alternative initiation. Isoform 1 and isoform 3 are widely expressed. Isoform 1 is largely nuclear, while isoforms 3 and 5 are cytoplasmic.

Protein type: Ubiquitin ligase; Ubiquitin conjugating system; Transcription, coactivator/corepressor; Tumor suppressor; EC 6.3.2.-; Nuclear receptor co-regulator

Cellular Component: ruffle; centrosome; protein complex; condensed nuclear chromosome; mitochondrial matrix; BRCA1-BARD1 complex; cytoplasm; plasma membrane; condensed chromosome; chromosome; nucleus; ribonucleoprotein complex

Molecular Function: enzyme binding; DNA binding; zinc ion binding; coenzyme F420-2 alpha-glutamyl ligase activity; RNA binding; metal ion binding; UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-D-alanyl-D-alanine ligase activity; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; ribosomal S6-glutamic acid ligase activity; damaged DNA binding; coenzyme F420-0 gamma-glutamyl ligase activity; ligase activity

Biological Process: genetic imprinting; dosage compensation, by inactivation of X chromosome; centrosome cycle; protein ubiquitination; negative regulation of histone H3-K4 methylation; positive regulation of histone H3-K4 methylation; fatty acid metabolic process; chromosome segregation; negative regulation of histone acetylation; DNA recombination; double-strand break repair; DNA replication; fatty acid biosynthetic process; negative regulation of fatty acid biosynthetic process; positive regulation of histone H3-K9 methylation; negative regulation of histone H3-K9 methylation; protein autoubiquitination; positive regulation of DNA repair; chordate embryonic development; postreplication repair; cell cycle; DNA repair; double-strand break repair via homologous recombination; regulation of cell proliferation; positive regulation of angiogenesis; DNA damage response, signal transduction resulting in induction of apoptosis; positive regulation of protein ubiquitination; response to estrogen stimulus; positive regulation of histone acetylation; positive regulation of transcription from RNA polymerase II promoter; response to ionizing radiation; lipid metabolic process; G2/M transition DNA damage checkpoint; negative regulation of transcription, DNA-dependent; centrosome duplication; response to DNA damage stimulus